CCDC167 Inhibitors
Chemical inhibitors of CCDC167 can play a significant role in modulating the activity of this protein through various mechanisms. CDK4/6 inhibitors such as Palbociclib, Ribociclib, and Abemaciclib specifically target cyclin-dependent kinases that are integral to the cell cycle's progression. By inhibiting CDK4 and CDK6, these compounds can disrupt the cell cycle at specific checkpoints, indirectly affecting CCDC167, which is dependent on the proper sequence of the cell cycle for its activity. This disruption can lead to the functional inhibition of CCDC167, as it may be unable to perform its role in the regulated environment of the cell cycle. Similarly, Omipalisib, a dual inhibitor of PI3K and mTOR, and other pan-PI3K inhibitors like ZSTK474 and Alpelisib, which specifically targets PI3Kα, can disrupt signaling pathways that are crucial for cell growth and survival. The PI3K/Akt/mTOR pathway, often engaged in cellular processes linked to cell cycle regulation, when inhibited, can affect the functionality of CCDC167.
Furthermore, mTOR inhibitors such as AZD8055, which has a potent effect on mTOR kinase activity, and Torin 1, which selectively targets both mTORC1 and mTORC2, can impede essential signaling required for cell proliferation. By targeting these complexes, the inhibitors can alter the cellular conditions necessary for CCDC167's involvement in cell cycle control. Dual PI3K/mTOR inhibitors like PF-04691502, GSK2126458, BEZ235 (Dactolisib), and BGT226 take a broad approach by obstructing both PI3K and mTOR pathways. These inhibitors cleave the communication lines that are essential for the processes that CCDC167 is a part of, thus leading to its functional inhibition. By curtailing these critical pathways, the inhibitors bring about a state where CCDC167's normal activity within the cell is compromised, affecting its role in the regulation of the cell cycle.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib specifically inhibits cyclin-dependent kinases CDK4 and CDK6. Since CCDC167 is involved in cell cycle regulation, the inhibition of CDK4/6 could disrupt the cell cycle progression, leading to the inhibition of CCDC167 activity as it is dependent on the cell cycle phases. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib is another inhibitor of CDK4 and CDK6. Similar to Palbociclib, Ribociclib's action on these kinases could impede the cell cycle-related functions of CCDC167, inhibiting its activity by preventing proper cell cycle progression where CCDC167 is active. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib selectively inhibits CDK4 and CDK6. As CCDC167 plays a role in cell cycle regulation, Abemaciclib's inhibition of these kinases could lead to a halt in cell cycle progression at stages essential for CCDC167 activity, thereby functionally inhibiting CCDC167. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
Omipalisib is a PI3K and mTOR inhibitor. The PI3K/Akt/mTOR pathway is pivotal for various cellular processes, including those related to cell cycle and survival where CCDC167 might be involved. Inhibition of this pathway can lead to the functional inhibition of CCDC167. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent inhibitor of mTOR kinase activity. By inhibiting mTOR, it affects the downstream processes that are crucial for cell survival and proliferation. As CCDC167 is involved in cell cycle regulation, AZD8055 could inhibit CCDC167 by disrupting these mTOR-dependent processes. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 selectively inhibits mTORC1 and mTORC2. By targeting both complexes of mTOR, Torin 1 can impede the cellular signaling essential for cell growth and proliferation, potentially leading to the inhibition of CCDC167, which is implicated in cell cycle control. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
Alpelisib specifically inhibits PI3Kα. If CCDC167 activity is linked to PI3Kα signaling, as many cell cycle processes are, then inhibition of PI3Kα by Alpelisib could result in the functional inhibition of CCDC167 due to disruption of this signaling pathway. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is an inhibitor of PI3K. It can inhibit cellular growth and proliferation pathways that are essential for cell cycle progression. Since CCDC167 has functions related to cell cycle, ZSTK474 could inhibit its activity by blocking the PI3K signaling that CCDC167 depends on. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $265.00 $1050.00 | ||
GSK2126458 is a highly potent inhibitor of PI3K and mTOR. It can significantly inhibit the signaling pathways essential for cell growth, survival, and proliferation. Through this inhibition, it is likely to lead to the functional inhibition of CCDC167, which is involved in cell cycle regulation. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
BEZ235 inhibits both PI3K and mTOR. It can block the signaling pathways required for cell growth and proliferation, likely leading to the inhibition of CCDC167's activity in cell cycle regulation by impeding necessary signaling and cellular environmental conditions. | ||||||